|
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (600200.SS) DCF -Bewertung
CN | Healthcare | Biotechnology | SHH
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200.SS) Bundle
Stürzen Sie Ihre Analyse und steigern Sie die Präzision mit unserem (600200SS) DCF -Taschenrechner! Mit realen Daten von Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. und anpassbaren Annahmen ermöglichen dieses Tool Sie, wie ein erfahrener Investor prognostiziert, analysieren und value (600200S).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,109.9 | 1,871.7 | 1,775.5 | 2,026.2 | 2,240.0 | 2,286.1 | 2,333.2 | 2,381.3 | 2,430.4 | 2,480.5 |
| Revenue Growth, % | 0 | -11.29 | -5.14 | 14.12 | 10.55 | 2.06 | 2.06 | 2.06 | 2.06 | 2.06 |
| EBITDA | 214.2 | -352.1 | 146.6 | 49.0 | 47.5 | 18.9 | 19.3 | 19.7 | 20.1 | 20.5 |
| EBITDA, % | 10.15 | -18.81 | 8.25 | 2.42 | 2.12 | 0.82655 | 0.82655 | 0.82655 | 0.82655 | 0.82655 |
| Depreciation | 91.0 | 87.7 | 51.3 | 49.3 | 45.9 | 74.9 | 76.4 | 78.0 | 79.6 | 81.2 |
| Depreciation, % | 4.31 | 4.69 | 2.89 | 2.43 | 2.05 | 3.27 | 3.27 | 3.27 | 3.27 | 3.27 |
| EBIT | 123.2 | -439.8 | 95.2 | -.3 | 1.6 | -56.0 | -57.1 | -58.3 | -59.5 | -60.7 |
| EBIT, % | 5.84 | -23.5 | 5.36 | -0.01562752 | 0.07153312 | -2.45 | -2.45 | -2.45 | -2.45 | -2.45 |
| Total Cash | 671.2 | 723.6 | 1,130.9 | 1,477.1 | 1,712.8 | 1,296.4 | 1,323.1 | 1,350.4 | 1,378.2 | 1,406.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 845.1 | 1,238.8 | 763.9 | 867.7 | 9.2 | 880.1 | 898.3 | 916.8 | 935.7 | 955.0 |
| Account Receivables, % | 40.05 | 66.19 | 43.02 | 42.82 | 0.4094 | 38.5 | 38.5 | 38.5 | 38.5 | 38.5 |
| Inventories | 215.4 | 154.8 | 126.5 | 112.6 | 107.3 | 164.4 | 167.8 | 171.2 | 174.7 | 178.3 |
| Inventories, % | 10.21 | 8.27 | 7.12 | 5.56 | 4.79 | 7.19 | 7.19 | 7.19 | 7.19 | 7.19 |
| Accounts Payable | 340.9 | 240.4 | 149.5 | 240.2 | 275.7 | 281.6 | 287.4 | 293.3 | 299.3 | 305.5 |
| Accounts Payable, % | 16.16 | 12.84 | 8.42 | 11.85 | 12.31 | 12.32 | 12.32 | 12.32 | 12.32 | 12.32 |
| Capital Expenditure | -97.5 | -44.2 | -24.8 | -41.7 | -82.6 | -64.6 | -65.9 | -67.3 | -68.7 | -70.1 |
| Capital Expenditure, % | -4.62 | -2.36 | -1.4 | -2.06 | -3.69 | -2.83 | -2.83 | -2.83 | -2.83 | -2.83 |
| Tax Rate, % | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 | 6.61 |
| EBITAT | 102.8 | -442.8 | 55.1 | -.3 | 1.5 | -48.7 | -49.7 | -50.7 | -51.7 | -52.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -623.2 | -833.1 | 494.1 | 7.9 | 864.2 | -960.6 | -54.9 | -56.0 | -57.2 | -58.4 |
| WACC, % | 4.94 | 5.13 | 4.66 | 5.13 | 5.05 | 4.98 | 4.98 | 4.98 | 4.98 | 4.98 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,106.1 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -61 | |||||||||
| Terminal Value | -6,180 | |||||||||
| Present Terminal Value | -4,846 | |||||||||
| Enterprise Value | -5,952 | |||||||||
| Net Debt | 11 | |||||||||
| Equity Value | -5,963 | |||||||||
| Diluted Shares Outstanding, MM | 719 | |||||||||
| Equity Value Per Share | -8.29 |
What You Will Receive
- Authentic JiangSu WuZhong Data: Comprehensive financials, including revenue and EBIT, based on both historical and projected data.
- Complete Customization: Modify all key variables (highlighted cells) such as WACC, growth %, and tax rates to fit your analysis.
- Real-Time Valuation Adjustments: Automated recalculations that allow you to assess how changes affect the fair value of JiangSu WuZhong (600200SS).
- Flexible Excel Template: Designed for effortless modifications, scenario analysis, and in-depth forecasting.
- Efficient and Precise: Eliminate the need to build models from scratch while ensuring accuracy and adaptability.
Key Features of JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200SS)
- Customizable Forecast Inputs: Adjust vital parameters such as revenue growth, EBITDA margin, and capital investments.
- Instant DCF Valuation: Quickly calculates intrinsic value, net present value (NPV), and other financial metrics.
- High-Precision Accuracy: Leverages JiangSu WuZhong's financial data for credible valuation results.
- Simplified Scenario Analysis: Easily explore various assumptions and assess different outcomes.
- Efficiency Booster: Skip the hassle of constructing intricate valuation models from the ground up.
How It Operates
- Download the Template: Gain immediate access to the Excel-based JWPD DCF Calculator for JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200SS).
- Input Your Inputs: Modify the yellow-highlighted cells to fit your growth expectations, WACC, profit margins, and other variables.
- Automatic Calculations: The model refreshes to reveal the intrinsic value of JiangSu WuZhong Pharmaceutical.
- Experiment with Scenarios: Explore various assumptions to assess potential shifts in valuation.
- Evaluate and Decide: Leverage the results for informed investment or financial strategy decisions.
Why Opt for This Calculator?
- Reliable Data: Authentic financial information from JiangSu WuZhong Pharmaceutical Development Co., Ltd. ensures trustworthy valuation outcomes.
- Flexible Options: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Efficiency Boost: Pre-configured calculations save you the time of building from the ground up.
- Professional-Quality Tool: Crafted for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly Interface: Simplified design and clear, step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling shares in JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200SS).
- Financial Analysts: Enhance valuation processes with pre-built financial models tailored for the pharmaceutical sector.
- Consultants: Provide clients with timely and precise valuation insights related to JiangSu WuZhong Pharmaceutical (600200SS).
- Business Owners: Gain insight into how major pharmaceutical companies like JiangSu WuZhong (600200SS) are valued to inform your own business strategies.
- Finance Students: Explore valuation techniques through practical examples using data from JiangSu WuZhong Pharmaceutical (600200SS).
Overview of Template Features
- Historical Data: Comprehensive records of JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s past financial performance and initial forecasts.
- DCF and Levered DCF Models: In-depth templates designed for calculating the intrinsic value of JiangSu WuZhong Pharmaceutical Development Co., Ltd. (600200SS).
- WACC Sheet: Pre-configured calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Customize key parameters such as growth rates, EBITDA margins, and CAPEX projections.
- Quarterly and Annual Statements: A thorough analysis of JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s financial data.
- Interactive Dashboard: Dynamic visualization of valuation outputs and forecasts.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.